85 Individual Cognitive Trajectories Post-Radiotherapy for Brain Metastases RESULTS Compliance Thirty-six out of the original 60 (60%) patient were eligible for analysis, having completed the 3-months follow-up NCA (Figure 1). Of the 24 patients eligible for ≥11-months follow-up, 14 (58%) patients completed this assessment. Reasons for noncompliance were poor medical condition, death, refusal because testing was considered too burdensome, and time constraints of the patient. Patients who did not complete the 3-months follow-up had a lower KPS than patients who did complete the 3 months follow-up (p = .001). More patient who completed the ≥11-months follow-up had BMs as their first symptom of cancer (i.e. synchronous diagnosis, 57%) than patients who did not complete the ≥11 months follow-up (10%; p = .019). None of the other characteristics as shown in Table 1 significantly differed between patient groups. Moreover, there were no differences regarding pre-radiotherapy cognitive performance (domain-level) or number of patients with a cognitive impairment between patients who completed or not-completed the 3-months NCA nor between patients who completed or notcompleted the ≥11-months NCA. Clinical characteristics Baseline sociodemographic and clinical characteristics are shown in Table 1. In total 36 patients (19 male) finished the 3-months follow-up NCA at a median of 16 weeks from baseline (IQR 14-17). Median long-term follow-up time was 61 weeks from baseline (IQR 52-76). The median age was 63 years, and the primary tumor was most frequently lung cancer (47%). Most patients received SRS (94%) for 2-4 BMs (39%). During the 3-months follow-up, intracranial progression was observed in 13/36 patients (36%) of which 3 patients had received additional radiotherapy for these new BMs before the follow-up NCA. From the 3-months to the ≥11-months followup NCA, intracranial progression was observed in 6/14 patients of which 5 patients had received additional radiotherapy for these new BMs before the ≥11-months follow-up NCA. 4
RkJQdWJsaXNoZXIy MTk4NDMw